The promise of a new and better class of mental health therapies lies within the chemistry of psychedelic compounds.
Our mission is to unlock it.
We're developing safe, FDA, EMA and Health Canada approved therapies for neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines that have the potential to deliver greater impact than current first-line treatments.
Our first clinical program is focused on accessible psilocybin-based drugs that deliver rapid therapeutic outcomes without perceptual side effects. By eliminating the side effects, this intervention can be administered to a broad cohort of patients.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Toronto, Ontario, Ca
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://diamondthera.com
- Keywords
- psychopharmacology, biotechnology, life sciences, neuropsychiatry, drug development, clinical trials, research, clinical drug development, psychopharmacology, psychedelic medicine.
- HQ
- Toronto, Ontario
Diamond Therapeutics Questions
Diamond Therapeutics's website is http://diamondthera.com
Diamond Therapeutics's LinkedIn profile is https://ca.linkedin.com/company/diamond-therapeutics
Diamond Therapeutics has
8 employees.
View email and phone details for 8
employees at Diamond Therapeutics.
Diamond Therapeutics's industry is
Pharmaceutical Manufacturing
Diamond Therapeutics's top competitors are
Cybin Inc,
20/20 Optimeyes Technologies,
Goodcap Pharmaceuticals Inc.,
Beckley Psytech,
Noa Therapeutics,
Creovalo,
Ripple Therapeutics,
Hdax Therapeutics,
Quantum Biopharma (Nasdaq: $qntm),
Paradox Immunotherapeutics.
Diamond Therapeutics's categories are Pharmaceutical Manufacturing
Diamond Therapeutics's founding year is 2018
